December 8, 2021 -- Applied Biomath and Celsius Therapeutics are collaborating on the development of a semimechanistic pharmacokinetic/receptor occupancy model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
Applied Biomath offers software and services to help de-risk and accelerate drug R&D. The company's approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common biosimulation strategies deployed, including systems pharmacology, mechanistic modeling, pharmacokinetic/pharmacodynamic modeling, bioinformatics, and clinical pharmacology.
Celsius Therapeutics will use the model developed by Applied Biomath to support human dose projections in IBD.
No terms of the agreement were disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
